PROV

Provident is a small, federally-chartered savings institution (13 branches, almost all in Riverside County, CA) whose earnings power is quietly eroding. Net income has fallen four straight years — $9.09M (FY2022) → $8.59M → $7.35M → $6.25M (FY2025), a -14.9% YoY drop — and diluted EPS slipped to $0.93 (-12.3%). The balance sheet is shrinking, not growing: total assets -2.1% to $1.25B, with liabilities and equity both contracting. The core problem is profitability: a 4.9% ROE is well below any reasonable cost of equity for a bank, meaning this franchise earns less than it costs to fund — the hallmark of a low-quality, rate-squeezed thrift. The MD&A's risk litany (interest-rate duration risk, deposit fluctuations, competitive deposit repricing, credit/ACL risk) is generic but real for a sub-$1.5B lender with no scale advantage.

What keeps this from being a sell is the balance sheet and capital return, not the income statement. Equity is $129M against 6.58M shares — roughly $19.60 book value per share — so at $17.21 the stock trades at ~0.88x book. That sub-book price is itself a partial justification: a 4.9% ROE should trade below book. Crucially, management is leaning into it, repurchasing $4.45M of stock (+71% YoY, shrinking the count -4.2%) and paying $3.77M in dividends (~3.3% yield). Buying back shares below book value is accretive to book value per share, and operating cash flow actually rose +53% to $8.69M against trivial capex ($530K), so the capital return is well-funded. There is no balance-sheet stress, no material litigation, and a solid $53.1M cash position.